About Cingulate
Cingulate is a company based in Kansas City (United States) founded in 2012 by Craig S Gilgallon and Shane J Schaffer. It operates as a Professional Services. Cingulate has raised $33 million across 6 funding rounds from investors including The Werth Family Foundation, Salem Investment Partners and Lincoln Park Capital. The company has 13 employees as of December 31, 2024. Cingulate offers products and services including CTx-1301, CTx-1302, and CTx-2103. Cingulate operates in a competitive market with competitors including Lyndra, Nura Bio, Healx, i2o Therapeutics and Cure Pharmaceutical, among others.
- Headquarter Kansas City, United States
- Employees 13 as on 31 Dec, 2024
- Founders Craig S Gilgallon, Shane J Schaffer
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cingulate Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-15.55 M33.95as on Dec 31, 2024
-
EBITDA
$-14.99 M32.4as on Dec 31, 2024
-
Total Equity Funding
$33 M (USD)
in 6 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jul 22, 2025
-
Investors
The Werth Family Foundation
& 2 more
-
Employee Count
13
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cingulate
Cingulate is a publicly listed company on the NASDAQ with ticker symbol CING in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cingulate
Cingulate offers a comprehensive portfolio of products and services, including CTx-1301, CTx-1302, and CTx-2103. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A medication developed for treating ADHD with precision dosing.
Another formulation created for ADHD treatment with controlled release.
A candidate developed for managing anxiety-related disorders effectively.
Funding Insights of Cingulate
Cingulate has successfully raised a total of $33M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $25.0M
-
First Round
First Round
(14 Nov 2013)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Post-IPO - Cingulate | Valuation |
investors |
|
| Apr, 2025 | Amount | Grant - Cingulate | Valuation |
investors |
|
| Jan, 2024 | Amount | Post-IPO - Cingulate | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cingulate
Cingulate has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include The Werth Family Foundation, Salem Investment Partners and Lincoln Park Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Private equity investments are directed toward North American opportunities.
|
Founded Year | Domain | Location | |
|
Nonprofit organization offering community aid, global assistance, and data-driven solutions.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cingulate
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cingulate
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cingulate Comparisons
Competitors of Cingulate
Cingulate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyndra, Nura Bio, Healx, i2o Therapeutics and Cure Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for rare diseases is developed.
|
|
| domain | founded_year | HQ Location |
Oral drug delivery solutions are provided via liquid technology platform.
|
|
| domain | founded_year | HQ Location |
Oral thin film-based drug delivery systems are developed.
|
|
| domain | founded_year | HQ Location |
Proprietary platform is utilized for extended-release CNS drug development.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cingulate
Frequently Asked Questions about Cingulate
When was Cingulate founded?
Cingulate was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Cingulate located?
Cingulate is headquartered in Kansas City, United States. It is registered at Kansas City, Missouri, United States.
Who is the current CEO of Cingulate?
Shane J Schaffer is the current CEO of Cingulate. They have also founded this company.
Is Cingulate a funded company?
Cingulate is a funded company, having raised a total of $33M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $219.84K, raised on Nov 14, 2013.
How many employees does Cingulate have?
As of Dec 31, 2024, the latest employee count at Cingulate is 13.
What does Cingulate do?
Cingulate Inc. is a clinical-stage biopharmaceutical company engaged in the development of innovative treatments for central nervous system disorders, particularly Attention DeficitHyperactivity Disorder (ADHD) and anxiety-related conditions. Two product candidates, CTx-1301 and CTx-1302, are being developed for the ADHD market, valued at approximately 18 billion annually in the US. Additionally, CTx-2103 is under development for the 5 billion US anxiety market. Proprietary technology, such as the Precision Timed Release Platform, is utilized to ensure precise once-daily dosing. The company operates within the healthcare and biotechnology sector, focusing on neurobiological solutions.
Who are the top competitors of Cingulate?
Cingulate's top competitors include Healx, Nura Bio and i2o Therapeutics.
What products or services does Cingulate offer?
Cingulate offers CTx-1301, CTx-1302, and CTx-2103.
Is Cingulate publicly traded?
Yes, Cingulate is publicly traded on NASDAQ under the ticker symbol CING.
Who are Cingulate's investors?
Cingulate has 3 investors. Key investors include The Werth Family Foundation, Salem Investment Partners, and Lincoln Park Capital.
What is Cingulate's ticker symbol?
The ticker symbol of Cingulate is CING on NASDAQ.